Ionis Pharmaceuticals Files Q1 2025 10-Q
Ticker: IONS · Form: 10-Q · Filed: Apr 30, 2025 · CIK: 874015
Sentiment: neutral
Topics: 10-Q, quarterly-filing, pharmaceuticals, revenue
TL;DR
IONIS Q1 2025 10-Q filed. Revenue streams detailed.
AI Summary
Ionis Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported revenue from various sources including Research and Development, Wainua Joint Development, and Collaborative Agreements. Specific financial figures for these revenue streams and other financial details are available within the filing.
Why It Matters
This filing provides investors with an update on Ionis Pharmaceuticals' financial performance and revenue streams for the first quarter of 2025, offering insights into their ongoing business operations.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing with no immediate red flags.
Key Numbers
- 20250331 — Report Period End Date (Indicates the end of the fiscal quarter being reported.)
- 20250430 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- IONIS PHARMACEUTICALS INC (company) — Filer
- 2855 GAZELLE COURT, CARLSBAD, CA 92010 (location) — Business Address
- ISIS PHARMACEUTICALS INC (company) — Former Company Name
FAQ
What were Ionis Pharmaceuticals' total revenues for the first quarter of 2025?
The filing indicates revenue from Research and Development, Wainua Joint Development, and Collaborative Agreements for the period of January 1, 2025, to March 31, 2025, but specific total dollar amounts are not detailed in this excerpt.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
When did the company change its name from ISIS PHARMACEUTICALS INC?
The company changed its name from ISIS PHARMACEUTICALS INC on March 28, 1993.
What is the company's Standard Industrial Classification (SIC) code?
The SIC code for Ionis Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What are the different types of revenue streams mentioned in the filing excerpt?
The filing excerpt mentions revenue from 'OtherCommercial', 'ResearchAndDevelopmentRevenue', 'WainuaJointDevelopmentRevenue', 'Royalty', 'Product', 'Commercial', and 'CollaborativeAgreementRevenue'.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 30, 2025 regarding IONIS PHARMACEUTICALS INC (IONS).